Neural Therapeutics Announces AGSM Results, CFO Appointment and Welcomes Positive Developments in the German Cannabis Market
Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") is pleased to announce the results of its annual general and special meeting of shareholders held on May 25, 2026 (the "Meeting"), including shareholder approval of the acquisition by Neural of the remaining 69.25% equity interest in CWE European Holdings Inc. ("CWE") not already owned by the Company, through a series of ancillary transa
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-06-12 7:30 AM EDT | Neural Therapeutics Inc.
Telescope Innovations to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub
Vancouver, British Columbia--(Newsfile Corp. - June 11, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), a leading developer of intelligent automation and advanced chemical manufacturing technologies, is pleased to announce it will be presenting at the Planet MicroCap Las Vegas 2026 conference on Wednesday, June 17th, 2026. At Planet MicroCap, Dr. Jeffrey Sherman will provide an update on Telesc
Technologies, Produits chimiques, Pharmaceutique
2026-06-11 8:00 AM EDT | Telescope Innovations Corp.
Custom Health Announces Closing of the Acquisition of InnovativeRx Operating Subsidiaries to Expand Integrated Medication Management Infrastructure Across North America
Strategic Acquisition: Custom Health announces the closing of the acquisition of substantially all of the operating assets of InnovativeRx US Holdings, Inc. ("InnovativeRx") to expand its integrated healthcare infrastructure across North America. InnovativeRx is an existing operational partner already utilizing Custom Health's proprietary AdhereNet® platform, enabling streamlined integration and workflow continuity. F
Technologies, Pharmaceutique, Santé
2026-06-10 7:00 AM EDT | Custom Health Holdings Inc.
Medexus Announces License and Supply Deal for UM171 Cell Therapy in Canada
Ontario and Chicago, Illinois--(Newsfile Corp. - June 9, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF)
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-06-09 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 11, 2026, at 12:01 a.m., Eastern Time
Gaithersburg, Maryland--(Newsfile Corp. - June 9, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), the owner of Molecule.ai, an artificial intelligence ("AI") driven platform for molecular discovery and early-stage drug development, and United Dogecoin, Inc., Shuttle Pharma's wholly owned subsidiary and a Dogecoin mining company, today announced that its board of directors have approved a proposed reverse stock split of its common stock at a
2026-06-09 8:30 AM EDT | Shuttle Pharmaceuticals Holdings Inc.
Herbal Dispatch Completes 452kg Multi Client Medical Cannabis Export Shipment To Europe
Vancouver, British Columbia--(Newsfile Corp. - June 9, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a cannabis commerce and international distribution platform, is pleased to announce the successful completion of a 452-kilogram international medical cannabis export shipment to several customers in Germany. While the shipment represents an important operational milestone, its gr
Pharmaceutique, Cannabis, Dispensaires de cannabis
2026-06-09 3:01 AM EDT | Herbal Dispatch Inc.
CBIH Advances Strategic Pathway to Bring VitaCookies' Science-Driven Functional Wellness Platform to Texas Consumers
Houston, Texas--(Newsfile Corp. - June 8, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public biotechnology company trading under the ticker symbol CBIH, today announced that it has completed and submitted the required documentation as part of its Texas licensing process related to the planned commercialization of VitaCookies, its cannabinoid-formulated functional wellness cookie line. CBIH intends to move forward carefully, with a focus on licensing and franchisi
Biotechnologies, Pharmaceutique, Cannabis, Santé
2026-06-08 7:00 AM EDT | Cannabis Bioscience International Holdings
BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - June 8, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) ("PreveCeutical"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, today announced that BioGene Therapeutics Inc. (the "Company"or 'BioGene"), a company that is a significant shareholder of, has appointed Ty Howton to BioGene's Board of Directors, effectiv
Biotechnologies, Pharmaceutique, Santé
2026-06-08 3:00 AM EDT | PreveCeutical Medical Inc.
Custom Health Holdings Inc. Announces Completion of Plan of Arrangement
Vancouver, British Columbia--(Newsfile Corp. - June 5, 2026) - Custom Health Holdings Inc. (formerly, Queue Ventures Ltd.) ("Custom Health" or the "Company"), further to its press release dated May 13, 2026, is pleased to announce the successful completion of its previously announced plan of arrangement under the Business Corporations Act (British Columbia) (the "Arrangement") with Custom Health, Inc. ("Custom Delaware"), pursuant to which, among other thing
Technologies, Pharmaceutique, Santé
2026-06-05 6:00 PM EDT | Custom Health Holdings Inc.
Telescope Innovations Founder and CTO, Professor Jason Hein, Receives 2026 SCI Canada LeSueur Memorial Award
Vancouver, British Columbia--(Newsfile Corp. - June 5, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company") congratulates its Founder and Chief Technology Officer, Professor Jason Hein, on receiving the 2026 SCI Canada LeSueur Memorial Award from the Society of Chemical Industry ("SCI").
Technologies, Produits chimiques, Pharmaceutique
2026-06-05 8:00 AM EDT | Telescope Innovations Corp.
InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements
Vancouver, British Columbia--(Newsfile Corp. - June 4, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), today announce that it had received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on June 3, 2026 informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing on Nasdaq. As previously di
Biotechnologies, Pharmaceutique
2026-06-04 5:00 PM EDT | InMed Pharmaceuticals
TempraMed Signs Agreement for Exclusive Distribution Partnership in Brazil, One of the Largest Diabetes and Biologics Markets Globally
Highlights TempraMed signs Agreement for exclusive distribution in Brazil with Mobil Saúde Comercial Ltda Brazil represents one of the world's largest markets for diabetes, GLP-1 therapies, and temperature-sensitive biologics1. Diabetes market alone reached USD $2.15 Billion in 2025 Partnership builds on TempraMed's recently granted Brazilian patent protecting th
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-06-04 7:00 AM EDT | TempraMed Technologies Ltd.
Theralase(R) Lists Warrants on the TSXV
Toronto, Ontario--(Newsfile Corp. - June 3, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that the TSX Venture Exchange ("TSXV") has accepted for listing up to 20,399,050 common share p
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-06-03 7:00 AM EDT | Theralase Technologies Inc.
Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors
Montreal, Quebec--(Newsfile Corp. - June 3, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the appointment of Dr. John Beaver to its Board of Directors. Dr. Beaver brings more than two decades of leadership experience across global pharmaceutical and biotechnology organizations. Dr. Beaver has held senior leadership position
Biotechnologies, Pharmaceutique, Santé
2026-06-03 3:15 AM EDT | Defence Therapeutics Inc.
Herbal Dispatch Inc. Appoints Jason Spatafora as Strategic Advisor
Vancouver, British Columbia--(Newsfile Corp. - June 3, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a leading cannabis e-commerce and distribution platform, is pleased to announce the appointment of Jason Spatafora as a strategic advisor to the Company. The appointment comes as Herbal Dispatch continues its transformation into a scalable, technology-enabled cannabis distribution platform. The Comp
Pharmaceutique, Cannabis, Dispensaires de cannabis
2026-06-03 3:01 AM EDT | Herbal Dispatch Inc.
Nextleaf Solutions Reports Fiscal Q2 2026 Results
Vancouver, British Columbia--(Newsfile Corp. - June 1, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) ("Nextleaf" or the "Company") a multi-patented Canadian cannabis processor, announced financial results for Q2 FY2026 (ended March 31, 2026), with gross revenue of $3,338,310 and gross profit of $914,536 (38% gross margin). The quarter reflects deliberate investment in commercial infrastructure, including a national sales agency, qualified export ready platform, and a second
Biotechnologies, Pharmaceutique, Cannabis, Extracteurs de cannabis
2026-06-01 9:30 AM EDT | Nextleaf Solutions Ltd.
Telescope Innovations Secures Third Self-Driving Lab Deployment with Major Global Pharmaceutical Company
Vancouver, British Columbia--(Newsfile Corp. - June 1, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), a leading developer of intelligent automation and advanced chemical manufacturing technologies, today announced that is has signed an agreement with a major global pharmaceutical company to deliver a Self-Driving Lab (SDL) platform at the company's European operations. The deployment, Telescope's third SDL pla
Technologies, Produits chimiques, Pharmaceutique
2026-06-01 8:00 AM EDT | Telescope Innovations Corp.
CBIH Completes Cannabinoid-Based Melanoma Patent Application Program Focused on Cannabinoid Science and Epigenetic Regulation
Houston, Texas--(Newsfile Corp. - June 1, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company focused on cannabinoid biotechnology, applied research, and therapeutic innovation, today announced the completion of a patent-ready melanoma research program focused on cannabinoid science, oncology biology, aging-related cellular stress, and epigenetic regulation. The Company views this milestone as part of its broader strategy to build research-driven int
Biotechnologies, Pharmaceutique, Cannabis, Santé
2026-06-01 7:00 AM EDT | Cannabis Bioscience International Holdings
Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product
Northvale, New Jersey--(Newsfile Corp. - June 1, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today announced that it has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for a generic drug product in the class of medications called anticoagulants. IQVIA reported branded product sa
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-06-01 7:00 AM EDT | Elite Pharmaceuticals, Inc.
Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to Its Board of Directors
Montreal, Quebec--(Newsfile Corp. - June 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the appointment of Dr. John Lambert to its Board of Directors, effective immediately. Dr. Lambert brings more than four decades of scientific leadership and pioneering expertise in the development of antibody-drug conjugates ("ADCs"), f
Biotechnologies, Pharmaceutique, Santé
2026-06-01 3:15 AM EDT | Defence Therapeutics Inc.